Cristiano Simone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3654373/publications.pdf

Version: 2024-02-01

71 papers 13,585 citations

35 h-index 95266 68 g-index

71 all docs

71 docs citations

71 times ranked 26974 citing authors

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	9.1	2,064
4	p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nature Genetics, 2004, 36, 738-743.	21.4	364
5	Physical and Functional HAT/HDAC Interplay Regulates Protein Acetylation Balance. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-10.	3.0	275
6	Deacetylase Inhibitors Increase Muscle Cell Size by Promoting Myoblast Recruitment and Fusion through Induction of Follistatin. Developmental Cell, 2004, 6, 673-684.	7.0	214
7	p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance. World Journal of Gastroenterology, 2014, 20, 9744.	3.3	181
8	Functional Interdependence at the Chromatin Level between the MKK6/p38 and IGF1/PI3K/AKT Pathways during Muscle Differentiation. Molecular Cell, 2007, 28, 200-213.	9.7	174
9	The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle, 2010, 9, 1091-1096.	2.6	154
10	Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging, 2018, 10, 3957-3985.	3.1	133
11	FOXO3a from the Nucleus to the Mitochondria: A Round Trip in Cellular Stress Response. Cells, 2019, 8, 1110.	4.1	131
12	A novel cell type-specific role of p38 $\hat{l}\pm$ in the control of autophagy and cell death in colorectal cancer cells. Cell Death and Differentiation, 2007, 14, 693-702.	11,2	130
13	p38 \hat{l} ± blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1 \hat{l} ±- to FoxO-dependent transcription. Cell Death and Differentiation, 2009, 16, 1203-1214.	11.2	111
14	Activation of MyoD-dependent transcription by cdk9/cyclin T2. Oncogene, 2002, 21, 4137-4148.	5.9	106
15	pRb: master of differentiation. Coupling irreversible cell cycle withdrawal with induction of muscle-specific transcription. Oncogene, 2006, 25, 5244-5249.	5.9	97
16	A SMYD3 Smallâ€Molecule Inhibitor Impairing Cancer Cell Growth. Journal of Cellular Physiology, 2015, 230, 2447-2460.	4.1	95
17	SWI/SNF: The crossroads where extracellular signaling pathways meet chromatin. Journal of Cellular Physiology, 2006, 207, 309-314.	4.1	87
18	A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing glucose levels. Cellular and Molecular Life Sciences, 2013, 70, 2015-2029.	5.4	85

#	Article	IF	CITATIONS
19	Inhibition of p38î± unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy, 2009, 5, 1030-1033.	9.1	72
20	Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors. PLoS ONE, 2015, 10, e0123092.	2.5	72
21	Physical interaction between pRb and cdk9/cyclinT2 complex. Oncogene, 2002, 21, 4158-4165.	5.9	66
22	Differentiation-Induced Radioresistance in Muscle Cells. Molecular and Cellular Biology, 2004, 24, 6350-6361.	2.3	66
23	In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). Neurogenetics, 2018, 19, 77-91.	1.4	65
24	Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1211-1224.	3.1	57
25	The longevity SNP rs2802292 uncovered: HSF1 activates stress-dependent expression of FOXO3 through an intronic enhancer. Nucleic Acids Research, 2018, 46, 5587-5600.	14.5	54
26	MyoD recruits the cdk9/cyclin T2 complex on Myogenic-genes regulatory regions. Journal of Cellular Physiology, 2006, 206, 807-813.	4.1	51
27	A homozygous frameshift mutation in the ESCO2 gene: Evidence of intertissue and interindividual variation in Nmd efficiency. Journal of Cellular Physiology, 2006, 209, 67-73.	4.1	48
28	Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38 \hat{l} ± modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Letters, 2014, 344, 110-118.	7.2	45
29	SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways. Cancers, 2020, 12, 142.	3.7	44
30	Clinical and Functional Characterization of a Novel Mutation in Lamin A/C Gene in a Multigenerational Family with Arrhythmogenic Cardiac Laminopathy. PLoS ONE, 2015, 10, e0121723.	2.5	43
31	FOXO3 on the Road to Longevity: Lessons From SNPs and Chromatin Hubs. Computational and Structural Biotechnology Journal, 2019, 17, 737-745.	4.1	43
32	Signal-Dependent Control of Autophagy and Cell Death in Colorectal Cancer Cell: The Role of the p38 Pathway. Autophagy, 2007, 3, 468-471.	9.1	41
33	Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Letters, 2012, 324, 98-108.	7.2	41
34	Signal-dependent regulation of gene expression as a target for cancer treatment: Inhibiting p38 \hat{l}_{\pm} in colorectal tumors. Cancer Letters, 2008, 265, 16-26.	7.2	39
35	SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget, 2016, 7, 75023-75037.	1.8	39
36	p38 $\hat{l}\pm$ Is Required for Ovarian Cancer Cell Metabolism and Survival. International Journal of Gynecological Cancer, 2010, 20, 203-211.	2.5	34

#	Article	IF	CITATIONS
37	Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300. Oncogene, 2004, 23, 2177-2187.	5.9	33
38	Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy. Cell Death and Disease, 2018, 9, 231.	6.3	33
39	Porous silicon surfaces – A candidate substrate for reverse protein arrays in cancer biomarker detection. Electrophoresis, 2007, 28, 4407-4415.	2.4	32
40	Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38. Autophagy, 2015, 11, 2102-2113.	9.1	27
41	Tumor-specific hyperactive low-molecular-weight cyclin E isoform detection and characterization in non-metastatic colorectal tumors. Cancer Biology and Therapy, 2006, 5, 198-203.	3.4	26
42	Abrogation of signal-dependent activation of the cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells. Cell Death and Differentiation, 2007, 14, 192-195.	11.2	24
43	Identification of murine $cdk10$: Association with Ets2 transcription factor and effects on the cell cycle. Journal of Cellular Biochemistry, 2006, 99, 978-985.	2.6	23
44	Sorafenib inhibits p38 \hat{l} ± activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biology and Therapy, 2012, 13, 1471-1481.	3.4	22
45	Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape. Cancers, 2019, 11, 414.	3.7	19
46	Cdk9â€55: A new player in muscle regeneration. Journal of Cellular Physiology, 2008, 216, 576-582.	4.1	18
47	Novel splice isoforms of STRADÎ \pm differentially affect LKB1 activity, complex assembly and subcellular localization Cancer Biology and Therapy, 2007, 6, 1627-1631.	3.4	16
48	Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality. IScience, 2020, 23, 101604.	4.1	14
49	New insight in cdk9 function: from Tat to MyoD. Frontiers in Bioscience - Landmark, 2001, 6, d1073.	3.0	13
50	Cyclin E and chromosome instability in colorectal cancer cell lines. Journal of Clinical Pathology, 2002, 55, 200-203.	1.9	13
51	Gastric polyposis and desmoid tumours as a new familial adenomatous polyposis clinical variant associated with APC mutation at the extreme $3\hat{a}\in^2$ -end. Journal of Medical Genetics, 2020, 57, 356-360.	3.2	12
52	From Genetics to Histomolecular Characterization: An Insight into Colorectal Carcinogenesis in Lynch Syndrome. International Journal of Molecular Sciences, 2021, 22, 6767.	4.1	12
53	Characterization of the rs2802292 SNP identifies FOXO3Aas a modifier locus predicting cancer risk in patients with PJS and PHTS hamartomatous polyposis syndromes. BMC Cancer, 2014, 14, 661.	2.6	11
54	Germline pathogenic variant in <i>PIK3CA</i> leading to symmetrical overgrowth with marked macrocephaly and mild global developmental delay. Molecular Genetics & Enomic Medicine, 2019, 7, e845.	1,2	11

#	Article	lF	CITATIONS
55	Pharmacological targeting of the novel \hat{i}^2 -catenin chromatin-associated kinase p38 \hat{i}^\pm in colorectal cancer stem cell tumorspheres and organoids. Cell Death and Disease, 2021, 12, 316.	6.3	11
56	Updates from the Intestinal Front Line: Autophagic Weapons against Inflammation and Cancer. Cells, 2012, 1, 535-557.	4.1	10
57	Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase. ChemBioChem, 2021, 22, 1597-1608.	2.6	8
58	Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies. Cancers, 2021, 13, 4427.	3.7	7
59	CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype. Journal of Experimental and Clinical Cancer Research, 2022, 41, 65.	8.6	7
60	Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38 <i<math>\hat{l}\pmKinase. Journal of Oncology, 2012, 2012, 1-7.</i<math>	1.3	6
61	A rare MSH2 mutation causes defective binding to hMSH6, normal hMSH2 staining, and loss of hMSH6 at advanced cancer stage. Human Pathology, 2014, 45, 2162-2167.	2.0	6
62	Characterization of a rare variant (c.2635-2A>G) of the <i>MSH2</i> gene in a family with Lynch syndrome. International Journal of Biological Markers, 2018, 33, 534-539.	1.8	6
63	Identifying novel SMYD3 interactors on the trail of cancer hallmarks. Computational and Structural Biotechnology Journal, 2022, 20, 1860-1875.	4.1	6
64	Chapter 15 Signal-Dependent Control of Autophagy-Related Gene Expression. Methods in Enzymology, 2009, 453, 305-324.	1.0	4
65	A novel STK11 gene mutation (c.388dupG, p.Glu130Glyfsa $$ —33) in a Peutz-Jeghers family and evidence of higher gastric cancer susceptibility associated with alterations in STK11 region aa 107-170. Genes and Diseases, 2022, 9, 288-291.	3.4	4
66	Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing. Cancers, 2021, 13, 4714.	3.7	3
67	APC Splicing Mutations Leading to In-Frame Exon 12 or Exon 13 Skipping Are Rare Events in FAP Pathogenesis and Define the Clinical Outcome. Genes, 2021, 12, 353.	2.4	2
68	Functional evidence of $\langle scp \rangle mTOR\hat{l}^2 \langle scp \rangle$ splice variant involvement in the pathogenesis of congenital heart defects. Clinical Genetics, 2021, 99, 425-429.	2.0	1
69	Correspondence on "Clinical spectrum of MTOR-related hypomelanosis of Ito with neurodevelopmental abnormalities,―by Carmignac et al Genetics in Medicine, 2021, 23, 2223-2224.	2.4	1
70	Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality. SSRN Electronic Journal, 0, , .	0.4	0
71	Identification and Somatic Characterization of the Germline PTEN Promoter Variant rs34149102 in a Family with Gastrointestinal and Breast Tumors. Genes, 2022, 13, 644.	2.4	0